Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 26 (12) , 2211-2216
Abstract
No abstract availableKeywords
Funding Information
- University of South Florida
This publication has 30 references indexed in Scilit:
- CAR T Cell Therapy–Related Cardiovascular Outcomes and ManagementJACC: Cardiooncology, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Toxicities of CD19 CAR‐T cell immunotherapyAmerican Journal of Hematology, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014